Abstract:Deubiquitinases (DUBs) play important roles in various human cancers and targeting DUBs is considered as a novel anticancer therapeutic strategy. Overexpression of ubiquitin specific protease 7 and 22 (USP7 and USP22) are associated with malignancy, therapy resistance, and poor prognosis in many cancers. Although both DUBs are involved in the regulation of similar genes and signaling pathways, such as histone H2B monoubiquitination (H2Bub1), c-Myc, FOXP3, and p53, the interdependence of USP22 and USP7 expression has never been described. In the study, we found that targeting USP7 via either siRNA-mediated knockdown or pharmaceutical inhibitors dramatically upregulates USP22 in cancer cells. Mechanistically, the elevated USP22 occurs through a transcriptional pathway, possibly due to desuppression of the transcriptional activity of SP1 via promoting its degradation upon USP7 inhibition. Importantly, increased USP22 expression leads to significant activation of downstream signal pathways including H2Bub1 and c-Myc, which may potentially enhance cancer malignancy and counteract the anticancer efficacy of USP7 inhibition. Importantly, targeting USP7 further suppresses the in vitro proliferation of USP22-knockout (USP22-Ko) A549 and H1299 lung cancer cells and induces a stronger activation of p53 tumor suppressor signaling pathway. In addition, USP22-Ko cancer cells are more sensitive to a combination of cisplatin and USP7 inhibitor. USP7 inhibitor treatment further suppresses in vivo angiogenesis and tumor growth and induced more apoptosis in USP22-Ko cancer xenografts. Taken together, our findings demonstrate that USP7 inhibition can dramatically upregulate USP22 in cancer cells; and targeting USP7 and USP22 may represent a more effective approach for targeted cancer therapy, which warrants further study.

Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.

USP7: Target Validation and Drug Discovery for Cancer Therapy

Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?

Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors

Inhibition of USP14 Deubiquitinating Activity As a Potential Therapy for Tumors with P53 Deficiency

Recent Insights into USP7: Construct, Pathophysiology, and Inhibitors

Identification of new leads against ubiquitin specific protease-7 (USP7): a step towards the potential treatment of cancers

Synthesis and Biological Evaluation of Thiazole Derivatives As Novel USP7 Inhibitors.

Validation of Catalytic Site Residues of Ubiquitin Specific Protease 2 (USP2) by Molecular Dynamic Simulation and Novel Kinetics Assay for Rational Drug Design

Structure-based Virtual Screening of Novel USP5 Inhibitors Targeting the Zinc Finger Ubiquitin-Binding Domain

USP13: Multiple Functions and Target Inhibition

Development of a highly reliable assay for ubiquitin-specific protease 2 inhibitors.

Cheminformatics-aided discovery of potential allosteric site modulators of ubiquitin-specific protease 7

Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells

Virtual screening of natural products targeting ubiquitin-specific protease 7

Discovery of Novel USP8 Inhibitors Via Ubiquitin-Rho-110 Fluorometric Assay Based High Throughput Screening.

A Selective USP1–UAF1 Inhibitor Links Deubiquitination to DNA Damage Responses

Gardenin B, a Natural Inhibitor for USP7: in Vitro Evaluation and in Silico Identification

Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy

Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy

In silico screening and computational evaluation of novel promising USP14 inhibitors targeting the palm-thumb pocket